Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases.
The last earnings update was 256 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Mereo BioPharma Group. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Mereo BioPharma Group's
is considered below, and whether this is a fair price.
Price based on past earnings
Mereo BioPharma Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
Mereo BioPharma Group's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Mereo BioPharma Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Mereo BioPharma Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Mereo BioPharma Group
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Mereo BioPharma Group's finances.
The net worth of a company is the difference between its assets and liabilities.
Mereo BioPharma Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Mereo BioPharma Group's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Mereo BioPharma Group's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 2.4x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Denise Scots-Knight, Ph.D. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She has Co-founded Mereo BioPharma Group plc in 2015 and has been its Chief Executive Officer since July 1, 2015. Dr. Scots-Knight serves as Director at Cerimon Pharmaceuticals, Inc. She has been an Executive Director of Mereo BioPharma Group plc since July 29, 2015. She served as a Director at OncoMed Pharmaceuticals, Inc. since October 2008 until September 28, 2018. She served as Chief Executive Officer and Managing Partner at Phase4 Partners Limited from December 2010 until July 2015 and served as its Director. She previously served Managing Director at Nomura Principal Finance Group Europe. Dr. Scots-Knight served as the Chairman of Supervisory Board at Nabriva Therapeutics AG from 2007 until August 25, 2016 and served as its Member since 2007 until August 25, 2016. She served as Deputy Chairperson of Supervisory Board at Evotec (Göttingen) AG. She served as a Director of Intercell Ag. She served as Director pf Albireo Pharma, Inc. since February 2008 until September 28, 2017. From April 2004 to December 2010, Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. From January 1999 to March 2004, Dr. Scots-Knight served as head of Healthcare Private Equity at Nomura International plc. She served as a Director of ViaCell, Inc. from October 2003 to April 9, 2007. She served as a Director of Idenix Pharmaceuticals, Inc. from May 2003 to August 5, 2014. Dr. Scots-Knight holds a Ph.D. and a B.Sc. (Hons) degree with honors from the University of Birmingham and was a Fulbright scholar at the University of California, Berkeley. She also holds a diploma in Company Direction from the Institute of Directors.
Denise's compensation has increased whilst company is loss making.
Denise's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
Mereo BioPharma Group
management team in years:
The tenure for the Mereo BioPharma Group management team is about average.
Richard Crispin Jones
CFO & Executive Director
Co-Founder & Chief Medical Officer
Co-Founder & Head of Corporate Development
Head of Intellectual Property
Therapy Area Head of Orphan Diseases
Head of Clinical Operations
Therapy Area Head of Respiratory Endocrinology
Head of Pharmaceutical Development
Board of Directors Tenure
Average tenure and age of the
Mereo BioPharma Group
board of directors in years:
The tenure for the Mereo BioPharma Group board of directors is about average.
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.